Comparing two drug combinations for newly diagnosed multiple myeloma with kidney failure
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new combination of drugs (daratumumab, bortezomib, and dexamethasone) against the usual combination (cyclophosphamide, bortezomib, and dexamethasone) in people with newly diagnosed multiple myeloma who also have kidney failure. The goal is to see if the new combination works better and helps protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that was diagnosed within the last 3 months.
- You have kidney failure that started within the last 3 months, with a GFR below 40 mL/min/1.73 m², serum creatinine above 2 mg/dL, or you are on dialysis.
- You have a specific kind of myeloma protein (called 'light chains') in your blood or urine.
- You are 18 years or older and able to do daily activities with minor help (ECOG 0-2), unless severe bone pain or fractures are the reason for needing more help.
- You have not had more than one cycle of standard myeloma treatment (cyclophosphamide, bortezomib, or dexamethasone) and the last dose was within 30 days.
- You have good heart, liver, and lung function, and no other serious health conditions that would interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares different combinations of medicines for people newly diagnosed with multiple myeloma who cannot safely get a stem cell transplant. It aims to find which drug plan works best and is tolerable for people with “frail” or “intermediate fit” health.
This Phase 3 trial tests a combination treatment approach for adults with newly diagnosed multiple myeloma, focusing on response and deeper remission. It may help by improving how well the disease is controlled early and measuring results beyond standard tests.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
This trial tests two different drug combinations for people newly diagnosed with multiple myeloma who are not getting a stem cell transplant right away. It compares one drug (elranatamab) to another (daratumumab), both given with a standard three-drug regimen called RVd Lite, to see which works better.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
This study tests a new combination of two drugs, teclistamab and pomalidomide, against the usual treatment of three drugs for multiple myeloma that has come back shortly after a standard treatment. The goal is to see if the new combination works better or is safer.
Hear when a new Myeloma Multiple trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.